Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent

Mani Salarian, Hua Yang, Ravi Chakra Turaga, Shanshan Tan, Jingjuan Qiao, Shenghui Xue, Zongxiang Gui, Guangda Peng, Hongwei Han, Pardeep Mittal, Hans E. Grossniklaus, Jenny J. Yang

Research output: Contribution to journalArticle

Abstract

The Liver is the most common organ for metastasis for various cancers, including uveal melanoma, the most common primary intraocular tumor. Uveal melanoma metastasizes to the liver in ~90% of patients, and results in death in almost all cases due to late detection and lack of effective treatment. There is a pressing unmet medical need to develop MRI contrast agents and imaging methodologies with desired sensitivity and specificity to overcome the high heterogeneous background and in vivo properties as well as reduced toxicity. Herein, we report the development of a collagen targeting protein contrast agent (ProCA32.collagen1), since collagen is a diagnostic biomarker and therapeutic target for many types of primary and metastatic cancers and the tumor microenvironment. In addition to a strong affinity to collagen I, ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68.0 ± 0.25 and 100.0 ± 0.32 mM−1 s−1 at 1.4 T, respectively, and 42.6 ± 1.0 and 217 ± 2.4 mM−1s−1 at 7.0 T per particle). ProCA32.collagen1 also has strong serum stability against degradation, resistance to transmetallation, and 102 and 1013-fold higher metal selectivity for Gd3+ over Ca2+ and Zn2+, respectively, compared to clinical contrast agents. ProCA32.collagen1 does not exhibit any cell toxicity for various cell lines. Sensitive detection of liver lesions in animal models can be achieved using multiple imaging methodologies, taking advantage of the dual relaxation property of ProCA32.collagen1. ProCA32.collagen1 enables sensitive and early stage detection of hepatic micrometastasis as small as 0.144 mm2 and two different tumor growth patterns. Further development of ProCA32.collagen1 has the potential to greatly facilitate non-invasive, early detection and staging of primary and metastatic liver cancers, and devising effective treatments.

Original languageEnglish (US)
Article number119478
JournalBiomaterials
Volume224
DOIs
StatePublished - Dec 2019

Fingerprint

Collagen
Liver
Magnetic resonance imaging
Contrast Media
Neoplasm Metastasis
Proteins
Tumors
Tumor Microenvironment
Toxicity
Imaging techniques
Neoplasms
Neoplasm Micrometastasis
Biomarkers
Protein Transport
Liver Neoplasms
Animals
Animal Models
Metals
Cells
Sensitivity and Specificity

Keywords

  • Collagen I
  • Liver metastasis
  • Magnetic resonance imaging
  • Protein contrast agent

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Salarian, M., Yang, H., Turaga, R. C., Tan, S., Qiao, J., Xue, S., ... Yang, J. J. (2019). Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent. Biomaterials, 224, [119478]. https://doi.org/10.1016/j.biomaterials.2019.119478

Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent. / Salarian, Mani; Yang, Hua; Turaga, Ravi Chakra; Tan, Shanshan; Qiao, Jingjuan; Xue, Shenghui; Gui, Zongxiang; Peng, Guangda; Han, Hongwei; Mittal, Pardeep; Grossniklaus, Hans E.; Yang, Jenny J.

In: Biomaterials, Vol. 224, 119478, 12.2019.

Research output: Contribution to journalArticle

Salarian, M, Yang, H, Turaga, RC, Tan, S, Qiao, J, Xue, S, Gui, Z, Peng, G, Han, H, Mittal, P, Grossniklaus, HE & Yang, JJ 2019, 'Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent', Biomaterials, vol. 224, 119478. https://doi.org/10.1016/j.biomaterials.2019.119478
Salarian, Mani ; Yang, Hua ; Turaga, Ravi Chakra ; Tan, Shanshan ; Qiao, Jingjuan ; Xue, Shenghui ; Gui, Zongxiang ; Peng, Guangda ; Han, Hongwei ; Mittal, Pardeep ; Grossniklaus, Hans E. ; Yang, Jenny J. / Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent. In: Biomaterials. 2019 ; Vol. 224.
@article{9d2373efdde84e8591fc4a620d8621d8,
title = "Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent",
abstract = "The Liver is the most common organ for metastasis for various cancers, including uveal melanoma, the most common primary intraocular tumor. Uveal melanoma metastasizes to the liver in ~90{\%} of patients, and results in death in almost all cases due to late detection and lack of effective treatment. There is a pressing unmet medical need to develop MRI contrast agents and imaging methodologies with desired sensitivity and specificity to overcome the high heterogeneous background and in vivo properties as well as reduced toxicity. Herein, we report the development of a collagen targeting protein contrast agent (ProCA32.collagen1), since collagen is a diagnostic biomarker and therapeutic target for many types of primary and metastatic cancers and the tumor microenvironment. In addition to a strong affinity to collagen I, ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68.0 ± 0.25 and 100.0 ± 0.32 mM−1 s−1 at 1.4 T, respectively, and 42.6 ± 1.0 and 217 ± 2.4 mM−1s−1 at 7.0 T per particle). ProCA32.collagen1 also has strong serum stability against degradation, resistance to transmetallation, and 102 and 1013-fold higher metal selectivity for Gd3+ over Ca2+ and Zn2+, respectively, compared to clinical contrast agents. ProCA32.collagen1 does not exhibit any cell toxicity for various cell lines. Sensitive detection of liver lesions in animal models can be achieved using multiple imaging methodologies, taking advantage of the dual relaxation property of ProCA32.collagen1. ProCA32.collagen1 enables sensitive and early stage detection of hepatic micrometastasis as small as 0.144 mm2 and two different tumor growth patterns. Further development of ProCA32.collagen1 has the potential to greatly facilitate non-invasive, early detection and staging of primary and metastatic liver cancers, and devising effective treatments.",
keywords = "Collagen I, Liver metastasis, Magnetic resonance imaging, Protein contrast agent",
author = "Mani Salarian and Hua Yang and Turaga, {Ravi Chakra} and Shanshan Tan and Jingjuan Qiao and Shenghui Xue and Zongxiang Gui and Guangda Peng and Hongwei Han and Pardeep Mittal and Grossniklaus, {Hans E.} and Yang, {Jenny J.}",
year = "2019",
month = "12",
doi = "10.1016/j.biomaterials.2019.119478",
language = "English (US)",
volume = "224",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent

AU - Salarian, Mani

AU - Yang, Hua

AU - Turaga, Ravi Chakra

AU - Tan, Shanshan

AU - Qiao, Jingjuan

AU - Xue, Shenghui

AU - Gui, Zongxiang

AU - Peng, Guangda

AU - Han, Hongwei

AU - Mittal, Pardeep

AU - Grossniklaus, Hans E.

AU - Yang, Jenny J.

PY - 2019/12

Y1 - 2019/12

N2 - The Liver is the most common organ for metastasis for various cancers, including uveal melanoma, the most common primary intraocular tumor. Uveal melanoma metastasizes to the liver in ~90% of patients, and results in death in almost all cases due to late detection and lack of effective treatment. There is a pressing unmet medical need to develop MRI contrast agents and imaging methodologies with desired sensitivity and specificity to overcome the high heterogeneous background and in vivo properties as well as reduced toxicity. Herein, we report the development of a collagen targeting protein contrast agent (ProCA32.collagen1), since collagen is a diagnostic biomarker and therapeutic target for many types of primary and metastatic cancers and the tumor microenvironment. In addition to a strong affinity to collagen I, ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68.0 ± 0.25 and 100.0 ± 0.32 mM−1 s−1 at 1.4 T, respectively, and 42.6 ± 1.0 and 217 ± 2.4 mM−1s−1 at 7.0 T per particle). ProCA32.collagen1 also has strong serum stability against degradation, resistance to transmetallation, and 102 and 1013-fold higher metal selectivity for Gd3+ over Ca2+ and Zn2+, respectively, compared to clinical contrast agents. ProCA32.collagen1 does not exhibit any cell toxicity for various cell lines. Sensitive detection of liver lesions in animal models can be achieved using multiple imaging methodologies, taking advantage of the dual relaxation property of ProCA32.collagen1. ProCA32.collagen1 enables sensitive and early stage detection of hepatic micrometastasis as small as 0.144 mm2 and two different tumor growth patterns. Further development of ProCA32.collagen1 has the potential to greatly facilitate non-invasive, early detection and staging of primary and metastatic liver cancers, and devising effective treatments.

AB - The Liver is the most common organ for metastasis for various cancers, including uveal melanoma, the most common primary intraocular tumor. Uveal melanoma metastasizes to the liver in ~90% of patients, and results in death in almost all cases due to late detection and lack of effective treatment. There is a pressing unmet medical need to develop MRI contrast agents and imaging methodologies with desired sensitivity and specificity to overcome the high heterogeneous background and in vivo properties as well as reduced toxicity. Herein, we report the development of a collagen targeting protein contrast agent (ProCA32.collagen1), since collagen is a diagnostic biomarker and therapeutic target for many types of primary and metastatic cancers and the tumor microenvironment. In addition to a strong affinity to collagen I, ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68.0 ± 0.25 and 100.0 ± 0.32 mM−1 s−1 at 1.4 T, respectively, and 42.6 ± 1.0 and 217 ± 2.4 mM−1s−1 at 7.0 T per particle). ProCA32.collagen1 also has strong serum stability against degradation, resistance to transmetallation, and 102 and 1013-fold higher metal selectivity for Gd3+ over Ca2+ and Zn2+, respectively, compared to clinical contrast agents. ProCA32.collagen1 does not exhibit any cell toxicity for various cell lines. Sensitive detection of liver lesions in animal models can be achieved using multiple imaging methodologies, taking advantage of the dual relaxation property of ProCA32.collagen1. ProCA32.collagen1 enables sensitive and early stage detection of hepatic micrometastasis as small as 0.144 mm2 and two different tumor growth patterns. Further development of ProCA32.collagen1 has the potential to greatly facilitate non-invasive, early detection and staging of primary and metastatic liver cancers, and devising effective treatments.

KW - Collagen I

KW - Liver metastasis

KW - Magnetic resonance imaging

KW - Protein contrast agent

UR - http://www.scopus.com/inward/record.url?scp=85072298461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072298461&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2019.119478

DO - 10.1016/j.biomaterials.2019.119478

M3 - Article

C2 - 31542517

AN - SCOPUS:85072298461

VL - 224

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

M1 - 119478

ER -